DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

WILMINGTON, Mass., Sept. 2   /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.  (NASDAQ:DUSA), a dermatology company that is developing and marketing Levulan  Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9, 2009 at 4:30 p.m. EDT at The New York Palace Hotel in New York.  Interested investors can access the live audio webcast of the presentation at http://www.dusapharma.com/. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.

  (Logo:  http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO )

  About DUSA Pharmaceuticals


DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan  photodynamic therapy (PDT) technology platform, and complementary dermatology products.  Levulan  PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp.  DUSA also markets other dermatology products, including ClindaReach .  DUSA is researching the use of Levulan  PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplanth recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH).  DUSA is based in Wilmington, Mass.  Please visit our Web site at http://www.dusapharma.com/. 

http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO

DATASOURCE: DUSA Pharmaceuticals, Inc.



CONTACT:  Chad Rubin, Investor Relations Contact, The Trout Group LLC,

[phone], for DUSA Pharmaceuticals, Inc.



Web Site:  http://www.dusapharma.com/ 

Copyright